Cargando…

Plasma Neurofilament Light and Future Declines in Cognition and Function in Alzheimer’s Disease in the FIT-AD Trial

BACKGROUND: Utilities of blood-based biomarkers in Alzheimer’s disease (AD) clinical trials remain unknown. OBJECTIVE: To evaluate the ability of plasma neurofilament light chain (NfL) to predict future declines in cognition and activities of daily living (ADL) outcomes in 26 older adults with mild-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Danni, Zhang, Lin, Nelson, Nathaniel W., Mielke, Michelle M., Yu, Fang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2021
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385429/ https://www.ncbi.nlm.nih.gov/pubmed/34514342 http://dx.doi.org/10.3233/ADR-210302

Ejemplares similares

Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in Subjective Cognitive Decline and Mild Cognitive Impairment
por: Giacomucci, Giulia, et al.
Publicado: (2022)

Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals
por: Benedet, Andréa L., et al.
Publicado: (2019)

Plasma and CSF neurofilament light: Relation to longitudinal neuroimaging and cognitive measures
por: Mielke, Michelle M., et al.
Publicado: (2019)

Plasma neurofilament light chain is associated with cognitive decline in non-dementia older adults
por: He, Lingxiao, et al.
Publicado: (2021)

Elevated plasma neurofilament light in aging reflects brain white‐matter alterations but does not predict cognitive decline or Alzheimer's disease
por: Nyberg, Lars, et al.
Publicado: (2020)

White matter hyperintensity, neurofilament light chain, and cognitive decline
por: Dhana, Anisa, et al.
Publicado: (2022)

Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes
por: Marks, Jordan D., et al.
Publicado: (2021)

Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease
por: Lin, Yung-Shuan, et al.
Publicado: (2018)

Plasma tau and neurofilament light chain as biomarkers of Alzheimer's disease and their relation to cognitive functions
por: Abed, Sadiruldeen Sami, et al.
Publicado: (2023)

Circulating Neurofilament Light Predicts Cognitive Decline in Patients With Post-stroke Subjective Cognitive Impairment
por: Wang, Jian-Hong, et al.
Publicado: (2021)

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients
por: Huang, Yanlu, et al.
Publicado: (2022)

Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease
por: Raket, Lars Lau, et al.
Publicado: (2020)

Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease
por: Lewczuk, Piotr, et al.
Publicado: (2018)

Cerebrospinal fluid and plasma neurofilament light relate to abnormal cognition
por: Osborn, Katie E., et al.
Publicado: (2019)

Plasma Aβ and neurofilament light chain are associated with cognitive and physical function decline in non-dementia older adults
por: He, Lingxiao, et al.
Publicado: (2020)

Plasma neurofilament light as a potential biomarker for cognitive decline in a longitudinal study of middle-aged urban adults
por: Beydoun, May A., et al.
Publicado: (2021)

Plasma Neurofilament Light Is Not Associated with Ongoing Neuroaxonal Injury or Cognitive Decline in Perinatally HIV Infected Adolescents: A Brief Report
por: van der Post, Julie, et al.
Publicado: (2022)

Examination of Neurofilament Light Chain Serum Concentrations, Physical Activity, and Cognitive Decline in Older Adults
por: Desai, Pankaja, et al.
Publicado: (2022)

Neurofilament light as a biomarker for motor decline in Parkinson’s disease
por: Liu, Yumei, et al.
Publicado: (2022)

Feasibility and preliminary effects of exercise interventions on plasma biomarkers of Alzheimer’s disease in the FIT-AD trial: a randomized pilot study in older adults with Alzheimer’s dementia
por: Yu, Fang, et al.
Publicado: (2022)

Effects of aerobic exercise on cognition and hippocampal volume in Alzheimer’s disease: study protocol of a randomized controlled trial (The FIT-AD trial)
por: Yu, Fang, et al.
Publicado: (2014)

Utility of Plasma Neurofilament Light in the 1Florida Alzheimer’s Disease Research Center (ADRC)
por: Barker, Warren, et al.
Publicado: (2021)

Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease
por: Dhiman, Kunal, et al.
Publicado: (2020)

Plasma Neurofilament Light Chain Is Associated with Cognitive Impairment after Posterior Circulation Stroke
por: Jiang, Lianyan, et al.
Publicado: (2022)

Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease
por: Batzu, Lucia, et al.
Publicado: (2022)

Comparing Neurofilament Light Chain Levels in Serum and Plasma
por: Kwon, Hyuk Sung, et al.
Publicado: (2023)

A Novel Neurofilament Light Chain ELISA Validated in Patients with Alzheimer’s Disease, Frontotemporal Dementia, and Subjective Cognitive Decline, and the Evaluation of Candidate Proteins for Immunoassay Calibration
por: Das, Shreyasee, et al.
Publicado: (2022)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer’s disease
por: Chatterjee, Pratishtha, et al.
Publicado: (2019)

Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression
por: Clark, Christopher, et al.
Publicado: (2021)

Plasma neurofilament light chain concentration in the inherited peripheral neuropathies
por: Sandelius, Åsa, et al.
Publicado: (2018)

Plasma neurofilament light chain concentration is increased in anorexia nervosa
por: Nilsson, Ida A. K., et al.
Publicado: (2019)

Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma
por: Sveijer, Malin, et al.
Publicado: (2022)

Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer’s disease
por: Weston, Philip S. J., et al.
Publicado: (2019)

The Role of Plasma Neurofilament Light Protein for Assessing Cognitive Impairment in Patients With End-Stage Renal Disease
por: Hou, Yi-Chou, et al.
Publicado: (2021)

Plasma Neurofilament Light Chains as Blood-Based Biomarkers for Early Diagnosis of Canine Cognitive Dysfunction Syndrome
por: Wu, Chung-Hsin, et al.
Publicado: (2023)

Recruiting and Screening Older Adults With Alzheimer’s Disease for the FIT-AD Trial
por: Yu, Fang, et al.
Publicado: (2021)

Plasma neurofilament light levels associate with muscle mass and strength in middle‐aged and older adults: findings from GenoFit
por: Pratt, Jedd, et al.
Publicado: (2022)

Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease
por: Lim, Nicholas S., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_me9imm1qr7tf5h4j9v4hobrs34